piflufolastat F 18

ApprovedSmall molecule

Novartis

piflufolastat F 18 is one of 26 small molecule programs targeting Prostate Cancer. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Prostate CancerApproved

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

piflufolastat F 18

Novartis

Approved

1 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Viagra

VViatris Specialty LLC

Preclinical

1 6

Duragesic

CCephalon

Preclinical

1 7

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 8

Prednisone/prednisolone

Roche

Preclinical

3 9

Triptorelin Pamoate

Ipsen

Preclinical

2 10

Ifex

BBaxter Healthcare Corporation

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Post-ApprovalActive, not recruiting

Prostate Cancer

NCT06074510

Q4 2026

Phase 2Active, not recruiting

PSMA PET

NCT05849298

Clinical

Trials by Indication[1]

Metastatic1 trial

Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC

Withdrawn·LLantheus Medical Imaging·Phase 2/3·NCT07084909

PSMA PET1 trial

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT05849298·49 enrolled

Prostate Cancer1 trial

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer

Active, not recruiting·LLantheus Medical Imaging·Phase 4·NCT06074510·274 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for piflufolastat F 18. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — piflufolastat F 18 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for piflufolastat F 18. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

piflufolastat F 18

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Metastatic1 trial

PSMA PET1 trial

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News